EQS Group-Ad-hoc: Medartis Holding AG / Key word(s): Investment 
Medartis announces strategic partnership with KeriMedical 
 
01-Dec-2020 / 06:59 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*Medartis Holding AG* 
Hochbergerstrasse 60E 
CH-4057 Basel 
 
PRESS RELEASE 
*Medartis acquires stake in KeriMedical and strengthens its extremities 
portfolio* 
 
Basel, Switzerland, 1 December 2020 - *Medartis Holding AG (SIX: MED) has 
acquired a strategic minority stake in KeriMedical, a Geneva-based company 
specialized in implants for hand and wrist surgery. The agreement includes a 
partnership in distribution to drive the international expansion of the 
KeriMedical portfolio, as well as in product development. With this 
partnership, Medartis takes a significant step towards becoming a complete 
solution provider in its strongest segment, hand and wrist. * 
 
Medartis has acquired a stake of 25% in KeriMedical effective 30 November 
2020 for a purchase price of CHF 10 million and is granted a seat on its 
Board of Directors. A significant share of the capital invested by Medartis 
will be used for access and development of the US market for the KeriMedical 
portfolio. This includes KeriMedical's flagship product, the Touch 
prosthesis, which is used to treat basal thumb osteoarthritis. Under the 
agreement, Medartis receives exclusive distribution rights in selected 
markets, among others in the US, Germany, Austria, UK and Australia to drive 
the international expansion of the KeriMedical portfolio. 
 
KeriMedical has extensive expertise in prosthetics for small joints, soft 
tissue fixation and nerve regeneration. The company is setting new standards 
in particular with its products in the area of thumb and finger joints, for 
example in the treatment of osteoarthritis in the hand, which affects more 
than 60% of all people aged over 55. With the combined portfolio, Medartis 
will expand its product offering for hand and wrist surgeons for the 
treatment of fractures, osteoarthritis, soft tissue and nerve injuries. 
 
In order to address this untapped market potential, KeriMedical and Medartis 
have further agreed to pursue a partnership in product development in the 
area of arthroplasty in small joints and soft tissue fixation in upper 
extremities. Furthermore, the partnership may create a basis for exploring 
opportunities in lower extremities over time. 
 
*About KeriMedical* 
Founded by Bernard Prandi and Dougal Bendjaballah in 2016, KeriMedical aims 
to develop and promote a full range of implants for hand and wrist surgery 
in line with the expectations and needs of both surgeons and patients. The 
KeriMedical team combines wide experience in orthopaedic surgery and has 
expertise at all levels of the value stream: research & development, 
manufacturing, quality, training, marketing and distribution of products. 
KeriMedical relies on a panel of internationally renowned surgeons with 
recognised experience in the field. These specialists contribute their 
clinical and medical expertise as part of the development and validation of 
new solutions. The company is headquartered in Geneva, employs around 70 
staff and operates in twenty European markets. For more information, please 
visit www.kerimedical.com [1]. 
 
*About Medartis* 
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of 
the world's leading manufacturers and providers of medical devices for 
surgical fixation of bone fractures for upper and lower extremities as well 
as for the craniomaxillofacial region. Medartis employs around 630 
individuals across its 13 locations, with products offered in over 50 
countries globally. Medartis is committed to providing surgeons and 
operating theatre personnel with the most innovative titanium implants and 
instruments as well as best in class service. For more information, please 
visit www.medartis.com [2]. 
 
*Contact* 
Patrick Christ 
Head Corporate Services 
Medartis Holding AG 
Phone: +41 61 633 34 70 
patrick.christ@medartis.com 
 
*Disclaimer* 
This communication does not constitute an offer or invitation to subscribe 
for or purchase any securities of Medartis Holding AG. This publication may 
contain certain forward-looking statements and assessments or intentions 
concerning the company and its business. Such statements involve certain 
risks, uncertainties and other factors which could cause the actual results, 
financial condition, performance or achievements of the company to be 
materially different from those expressed or implied by such statements. 
Readers should therefore not place reliance on these statements, 
particularly not in connection with any contract or investment decision. The 
company disclaims any obligation to update these forward-looking statements, 
assessments or intentions. Further, neither the company nor any of its 
directors, officers, employees, agents, counsel or advisers nor any other 
person makes any representation or warranty, express or implied, as to, and 
accordingly no reliance should be placed on, the accuracy or completeness of 
the information contained herein or of the views given or implied. 
 
End of ad hoc announcement 
Language:    English 
Company:     Medartis Holding AG 
             Hochbergerstrasse 60E 
             4057 Basel 
             Switzerland 
Phone:       +41 61 633 34 34 
Fax:         +41 61 633 34 00 
E-mail:      info@medartis.com 
Internet:    www.medartis.com 
ISIN:        CH0386200239 
Valor:       38620023 
Listed:      SIX Swiss Exchange 
EQS News ID: 1151636 
 
End of Announcement EQS Group News Service 
 
1151636 01-Dec-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1bd6c68f7aceaeb0da306af083d88562&application_id=1151636&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ac1a9388ff4c0c3cae80f1661ff5fc2d&application_id=1151636&site_id=vwd&application_name=news

(END) Dow Jones Newswires

December 01, 2020 00:59 ET (05:59 GMT)